Studies of tirzepatide in people
218 studies gave tirzepatide to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
| Randomized trial16 weeks | 36 peopleType 2 diabetes | Diabetes, obesity & metabolism, Nov 8, 2026 | |
down: Decreases predicted 10-year cardiovascular disease riskDifference versus placebo −2.4 percentage points (95% CI −3.4 to −1.4); estimated HR 0.77 (95% CI 0.69–0.85) | Randomized trial112 weeks, including 52 weeks of randomized maintenance | 133 peopleadultsObesity or overweight without diabetes or baseline cardiovascular disease; continued maximum tolerated dose versus switching to placebo after 60 weeks of tirzepatide | AHA Scientific Sessions 2026 abstract, Nov 2, 2026 |
down: Decreases total first and recurrent MACE-5 eventsrate ratio 0.87 (95% CI 0.80–0.95); 1,489 versus 1,696 total events | Randomized trial | 13,165 peopleBothmean 64.1 yearsMidlife adults; type 2 diabetes and established atherosclerotic cardiovascular disease | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Improves functional capacity down: Decreases body weight | Trial24 weeks | 120 peopleBoth61±9 yearsMidlife adults; Older adults; HFpEF with or without type 2 diabetes; in addition to guideline-directed therapy | ESC Congress 2026 abstract, Oct 26, 2026 |
down: Decreases HbA1c-1.5% up: Increases serum albumin down: Decreases alanine transaminase | Treated cohort24 weeks | 88 peoplePatient cohorts | Endocrine journal, Sep 29, 2026 |
down: Decreases body weight−6.50 kg [−8.03,−4.97] down: Decreases body fat mass−3.50% [−6.66, −0.34] up: Increases lean body mass3.40% [0.40, 6.40] | Review of trialsWeek 72 SURMOUNT-1, Week 68 STEP 1 | ≥18 years of ageAdults with obesity (BMI ≥ 30 kg/m), or overweight (BMI ≥ 27 kg/m) with ≥1 obesity-related complication (ORC), without type 2 diabetes (T2D) | International journal of obesity (2005), Sep 28, 2026 |
up: Increases high molecular weight adiponectin78.9% and 88.4% vs 0.9% down: Decreases C-reactive protein-55.1% and -65.3% vs -17.7% down: Decreases glucose AUC | Randomized trial72 weeks | 225 peopleadultsPatient cohorts | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, Sep 19, 2026 |
down: Decreases prediabetes down: Decreases waist-to-height ratio | Randomized trial176 weeks | 690 people64.6% were womenmean (SD) age 48.5 years (11.7)Participants with obesity or overweight with at least one weight-related complication and prediabetes | Obesity pillars, Sep 18, 2026 |
no change: Has no effect on atrial fibrillationpooled OR 2.20 (95% CrI, 0.81-6.75) up: Raises the risk of arrhythmiapooled OR 1.84 (95% CrI, 1.04-3.90) | Review of trials | 6,515 people pooledadultsAtrial arrhythmia pooled with atrial fibrillation | Journal of the American Heart Association, Sep 9, 2026 |
down: Decreases apnea-hypopnea index down: Decreases sleep apnea-specific hypoxic burden down: Decreases body weight | Randomized trial52 weeks | BothadultsAdults with moderate-to-severe OSA and obesity | Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, Aug 31, 2026 |
down: Decreases HbA1c down: Decreases body weight | Randomized trial2 y | In adults with early uncontrolled T2D | Annals of internal medicine, Aug 31, 2026 |
down: Decreases body weight-19.28% (95% CI -20.39% to -18.16%) versus placebo | Review of trials | 24,214 people pooledadultsPatient cohorts | BMJ medicine, Aug 27, 2026 |
| Randomized trial176 weeks | 1,032 peopleadultsParticipants with obesity or overweight with at least one weight-related complication and prediabetes | Journal of the Endocrine Society, Aug 19, 2026 | |
down: Lowers the risk of hypertension-related eventsRR 0.40, 95% CI 0.26–0.60 up: Raises the risk of hypotension-related eventsRR 2.45, 95% CI 1.35–4.45 | Review of trials | 47,332 people pooledPatient cohorts | Endocrine, Aug 15, 2026 |
down: Decreases HbA1c down: Decreases FIB-4 indexP < 0.001 down: Decreases hepatic steatosis index | Treated cohort6 months | 182 peopleAfter switching from GLP-1 receptor agonists | Journal of diabetes and its complications, Aug 14, 2026 |
up: Increases composite cardiometabolic triple endpoint achievement | Randomized trial72 to 88 weeks | Adults, obesity (body mass index [BMI] ≥30 kg/m2) or overweight (BMI ≥27 kg/m2 with at least one weight-related comorbid condition), without and with type 2 diabetes | PloS one, Aug 13, 2026 |
down: Decreases predicted 10-year cardiovascular disease riskARR -1.92% at week 72 | Randomized trial72 weeks | 962 peoplePeople with obesity/overweight and prediabetes, SURMOUNT-1 post hoc analysis | European journal of preventive cardiology, Aug 10, 2026 |
down: Lowers the risk of cardiovascular diseaseOR 0.82, 95% CI 0.72-0.93 down: Decreases mortalityOR 0.72, 95% CI 0.64-0.82 | Review of trialsat least 40 weeks | Patient cohorts | Diabetes, obesity & metabolism, Jul 30, 2026 |
down: Lowers the risk of heart failureHR 0.66 (95% CI 0.38, 1.18) for women, 0.61 (95% CI 0.33, 1.13) for men up: Improves kansas City Cardiomyopathy Questionnaire Clinical Summary Score+8.1 (95% CI 3.5, 12.7) in women and +5.5 (95% CI 0.9, 10.1) in men up: Improves 6-minute walk distance+18 (95% CI 5, 31) m for women vs +15 (95% CI −2, 31) m for men | Randomized trial52 weeks | 731 people393 (53.8%) were women and 338 (46.2%) were menaged ≥40 yearsIn women and men | JACC. Heart failure, Jul 7, 2026 |
up: Improves insulin sensitivity41% vs 10%, p<0.0001 up: Improves metabolic flexibility of adipocytes3.2 vs 0.6 μM, p=0.048 | Randomized trial6 weeks | 30 peopleadults with BMI 27-39.9At week 6, with weight loss matched to hypocaloric diet | ADA Scientific Sessions 2026 abstract, Jun 7, 2026 |
down: Lowers the risk of heart failureOR 0.55 (95% CI 0.33-0.92) | Review of trials | 205,889 people pooledBothmean 63.53 years (SD 0.42)Patient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
down: Decreases body weight-14.6% (95% CI -15.5 to -13.8) up: Raises the risk of nauseaOR 3.9 (95% CI 3.2-5.0) | Review of trials | 13,508 people pooledadultsPatient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
down: Decreases body weight-12.5 kg (-14%) from baseline up: Improves insulin sensitivity+60% | Randomized trial22 weeks | 63 peopleadultsPatient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
up: Improves physical health-related quality of life up: Improves weight-related quality of life up: Improves ability to perform daily activities | Randomized trial2 years | 794 peoplemean 53.5 yearsMidlife adults; Patient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
down: Decreases Joslin Kidney Panel proteins12 of 21 proteins significantly lowered | Randomized trial52 weeks | 106 peoplePatient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
no change: Has no effect on diabetic retinopathymean change -0.22 ETDRS points (p=0.27); between-treatment p=0.96 up: Increases diabetic retinopathy severitymean ETDRS change +0.30 (p=0.04); between-treatment p=0.63 down: Decreases HbA1c-2.18% (TZP) vs -1.28% (dula) at six months | Randomized trialsix months | 449 peopleIn patients without baseline DR | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
down: Decreases HbA1c-0.77% (95% CI −0.98 to −0.56) down: Decreases body weight-6.9 kg (95% CI−8.3 to −5.5) | Randomized trial40-week treatment period | 282 people146 (51.8%) males and 136 (48.2%) femalesmean overall age of 57.6 years (SD 9.8)Adults with T2D with inadequate glycemic control | BMJ open diabetes research & care, Mar 30, 2026 |
down: Decreases body weight−10.2% ± 2.5 vs −9.8% ± 2.9 down: Decreases fat mass−13.4% ± 2.8 vs −10.2% ± 3.1 | Trial12 weeks | 60 peopleAdults with obesity undergoing TZP therapy | Nutrients, Mar 29, 2026 |
down: Lowers the risk of cardiovascular and kidney outcomesHR 0.84, 95% CI 0.79-0.90 up: Raises the risk of gastrointestinal adverse events | Randomized trialmedian (IQR) treatment duration of 46.9 (34.6-50.6) months | 13,165 people9348 patients (71.0%) were male and 3817 were female (29.0%)mean (SD) age was 64 (8.8) yearsPatients at least 40 years of age with type 2 diabetes and established atherosclerotic cardiovascular disease | JAMA cardiology, Mar 29, 2026 |
up: Improves ACR50 and >=10% weight reduction31.7% vs 0.8% up: Improves ACR50 response33.5% vs 20.4% down: Decreases psoriasis severity | Randomized trial36 weeks | 271 people69.7% of participants were femalemean age was 55.0 (SD 11.9) yearsParticipants with active PsA and overweight in the presence of at least one weight‐related comorbid condition or active PsA and obesity | Arthritis & rheumatology (Hoboken, N.J.), Mar 28, 2026 |
no change: Has no effect on overall adverse eventsRR 1.04 [0.98-1.10] up: Increases treatment discontinuation due to adverse eventsRR 1.32 [1.20-1.45]; 32% increased risk up: Increases HbA1c below 7.0% target achievementRR 1.48 [1.33-1.64] | Review of trials≥26 weeks | 13,590 people pooledadultsAdults with type 2 diabetes | Healthcare (Basel, Switzerland), Mar 27, 2026 |
no change: Has no effect on acute pancreatitisRR 0.78, 95% CI 0.29-2.09 | Review of trialsshort-to-moderate follow-up | 15,471 people pooled10 mg vs 5 mg comparison | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], Mar 27, 2026 |
no change: Has no effect on mortalityodds ratio 1.02 (95% CI 0.57 to 1.81) no change: Has no effect on serious adverse eventsodds ratio 0.98 (95% CI 0.82 to 1.17) up: Raises the risk of gastrointestinal non-serious adverse events | Review of trials | 8,043 people pooledPlacebo-controlled trials in patients at increased risk of cardiovascular events; 21 trials | BMC medicine, Mar 27, 2026 |
down: Decreases hypoattenuated leaflet thickening8.4% vs 21.6%; p = 0.002 down: Decreases paravalvular leak10.7% vs 25.3%; p = 0.006 down: Decreases C-reactive proteinmarked reduction, not quantified | Randomized trial6 months | 260 peopleIn obese patients undergoing transfemoral TAVR, assessed at 6 months | Cardiovascular revascularization medicine : including molecular interventions, Mar 23, 2026 |
up: Increases ≥ 5% weight lossRR 7.17 [95% CI 4.38-11.73] down: Decreases body weight-16.48% [-21.70 to -11.27] up: Raises the risk of nausea and vomitingRR 3.64 [2.40-5.52] | Review of trials | 58,976 people pooledadultsType 2 diabetes, versus placebo | Diabetes, obesity & metabolism, Mar 23, 2026 |
up: Increases rapid weight loss response (at least 15% body weight reduction by Week 24)44% vs 21% rapid responders up: Increases achievement of body weight reduction thresholds | Randomized trial24 weeks | Proportion of rapid responders compared with semaglutide | The American journal of medicine, Mar 20, 2026 |
down: Decreases body weight-12.86% (10 mg) and -13.95% (15 mg) versus liraglutide down: Decreases triglyceride | Review of trials | adultsPatient cohorts | Advances in therapy, Mar 12, 2026 |
down: Decreases body weight−21.3% (95% CI, −23.9% to −18.7%) | Randomized trial72 weeks (SURMOUNT-1 and SURMOUNT-3) or 88 weeks (SURMOUNT-4) | 442 peopleBothadults, mean age 48.0 to 51.8 yearsParticipants with obesity or overweight with 1 or more weight-related conditions, excluding diabetes | JAMA network open, Mar 2, 2026 |
no change: Has no effect on major adverse cardiovascular eventsHR 0.92; 95 % CI 0.83 to 1.01; P = 0.09 down: Lowers the risk of all-cause deathHR 0.84; 95 % CI 0.75 to 0.94 | Randomized trialmedian follow-up four years | Non-inferior but not superior | Revue medicale de Liege, Mar 1, 2026 |
down: Decreases body mass index-8.90 vs -3.65 kg/m2 (SURMOUNT-1); -10.47 vs -5.20 kg/m2 (SURMOUNT-4) up: Improves cardiometabolic risk factors up: Improves BMI category81.8% (SURMOUNT-1); 91.6% (SURMOUNT-4) | Randomized trial72 weeks (SURMOUNT-1); 88 weeks (SURMOUNT-4) | In participants who shifted to a lower BMI category | American journal of preventive cardiology, Feb 25, 2026 |